Phase I/II clinical trial of WT1 peptide vaccine therapy for lung, breast, pancreas, stomach, and colorectal cancer

ABSTRACT: Interventions: Seven doses of HLA-A*24-restricted WT1 peptide (3 mg) emulsified with 1-2KE of OK-432 adjuvant will be intradermally injected on bilateral axillary and inguinal areas every 2 weeks. Injection schedule can be changed within 3 days. Primary outcome(s): Ratios of adverse events PFS: Progression free survival, Overall survival Study Design: Single arm Non-randomized

DISEASE(S): Lung, Breast, Pancreas, Stomach, And Colorectal Cancer

PROVIDER: 2626405 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR